The ROCK-ALS trial is a multicenter, interventional, randomized, controlled phase IIa trial assessing the safety, tolerability and efficacy of Fasudil in patients with amyotrophic lateral sclerosis. The trial protocol has now been approved by the regulatory authorities and patients are now recruited in centers in Germany, France and Switzerland. Information about trial centers, inclusion/exclusion criteria, treatment schedule can be found on this web site or with the local investigators. Please refresh this site to see the latest changes.

Funded in the scope of the EU E-Rare program 2016 through BMBF (Funding number: 01GM1704A), ANR and SNF.